We are live on ! Find out more
NXTC icon

NextCure

43 hedge funds and large institutions have $24M invested in NextCure in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more capital invested

Capital invested by funds: $19.6M → $24M (+$4.34M)

0.01% more ownership

Funds ownership: 3.98%3.99% (+0.01%)

0% more funds holding

Funds holding: 4343 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

Holders
43
Holders Change
Holders Change %
0%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
7
Reduced
10
Closed
5
Calls
$108K
Puts
Net Calls
+$108K
Net Calls Change
-$123K

NXTC Hedge Fund Activity: Q2 2023 in Review

43 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q2 2023, worth a combined $24M — up 22% from $19.6M a quarter earlier.

Fund positioning in NXTC was balanced in Q2 2023: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 10 trimmed.

The largest buyer was Acuitas Investments, opening a new position worth an estimated $471K. The largest seller was Morgan Stanley, cutting an estimated $194K.

  • 43 institutional investors held NextCure (NXTC) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $24M of NextCure stock for Q2 2023, up 22% quarter-over-quarter.
  • 5 funds opened new NextCure positions in Q2 2023 and 5 closed out, a net change of 0 holders.
  • The largest NextCure buyer in Q2 2023 was Acuitas Investments, an estimated $471K added.
  • The largest NextCure seller in Q2 2023 was Morgan Stanley, an estimated $194K sold.

Based on aggregated 13F filings for Q2 2023.